Stockscreener 앱 받기
304.84
0.74%
-2.26
시간 외 거래:
304.84
전일 마감가:
$307.10
열려 있는:
$307.12
하루 거래량:
725.86K
Relative Volume:
0.90
시가총액:
$21.45B
수익:
$2.20B
순이익/손실:
$402.20M
주가수익비율:
54.83
EPS:
5.56
순현금흐름:
$280.80M
1주 성능:
+5.93%
1개월 성능:
+5.36%
6개월 성능:
+7.24%
1년 성능:
+67.32%
1일 변동 폭
$304.26
$311.55
1주일 범위
$276.46
$322.80
52주 변동 폭
$180.31
$329.33
인슐렛 코퍼레이션 Stock (PODD) Company Profile
명칭
Insulet Corporation
전화
978-600-7000
주소
100 NAGOG PARK, ACTON, MA
PODD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
304.84 | 21.62B | 2.20B | 402.20M | 280.80M | 5.56 |
|
ABT
Abbott Laboratories
|
131.36 | 233.71B | 43.11B | 13.98B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
102.75 | 152.83B | 18.49B | 2.51B | 3.23B | 1.68 |
|
SYK
Stryker Corp
|
376.67 | 144.35B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.74 | 119.00B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.16 | 46.00B | 5.69B | 4.14B | 577.90M | 6.96 |
인슐렛 코퍼레이션 Stock (PODD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-16 | 개시 | Truist | Buy |
| 2025-05-30 | 개시 | Goldman | Buy |
| 2025-05-13 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-04-29 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-03-06 | 개시 | RBC Capital Mkts | Outperform |
| 2024-11-06 | 개시 | Bernstein | Outperform |
| 2024-05-30 | 개시 | Redburn Atlantic | Buy |
| 2024-05-07 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-08-21 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-08-21 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-01-26 | 개시 | Wolfe Research | Peer Perform |
| 2022-11-04 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | 개시 | Barclays | Equal Weight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-02-03 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2022-02-02 | 업그레이드 | UBS | Neutral → Buy |
| 2022-01-31 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-07-21 | 재개 | Cowen | Outperform |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-01 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-07-28 | 개시 | Wells Fargo | Overweight |
| 2020-04-24 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | 개시 | BofA/Merrill | Neutral |
| 2020-03-31 | 다운그레이드 | Berenberg | Buy → Hold |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2019-12-10 | 개시 | CFRA | Sell |
| 2019-10-23 | 개시 | Stifel | Hold |
| 2019-10-18 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2019-10-04 | 다운그레이드 | UBS | Buy → Neutral |
| 2019-10-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-08-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-06-10 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2018-04-20 | 개시 | Berenberg | Buy |
| 2018-02-22 | 재확인 | Barclays | Overweight |
| 2018-01-08 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | 개시 | Barclays | Overweight |
모두보기
인슐렛 코퍼레이션 주식(PODD)의 최신 뉴스
Insulet Corp: Strong Financial Position and Competitive Strengths - AInvest
Why Insulet (PODD) is a Top Growth Stock for the Long-Term - Yahoo Finance
Insulin pump makers Tandem and Insulet post contrasting Q2 results - MSN
Quant Strategy Flags Insulet Corporation for EntryTrade Scanner With Buy Zone Alerts Flagged - beatles.ru
Insulet's Insider Activity and Executive Compensation Transparency: A Governance and Investor Sentiment Analysis - AInvest
Research Alert: CFRA Maintains Hold Opinion On Shares Of Insulet Corporation - 富途牛牛
RBC Capital Raises PT for Insulet to $350, Maintains Outperform Rating - AInvest
Insulet Corporation shares rise 2.61% intraday after multiple brokerages raised price targets. - AInvest
Insulet (PODD) Is Up 5.3% After Raising Full-Year Revenue Guidance on Strong Q2 Sales – Has The Bull Case Changed? - simplywall.st
Baird Adjusts Price Target on Insulet to $360 From $350, Maintains Outperform Rating - MarketScreener
Insulet stock price target raised to $350 from $330 at RBC Capital - Investing.com Canada
Bernstein raises Insulet stock price target to $400 on type 2 diabetes growth - Investing.com Nigeria
RBC Raises Price Target on Insulet to $350 From $330, Keeps Outperform Rating - MarketScreener
Insulet price target raised to $350 from $330 at RBC Capital - TipRanks
Insulet Corporation (PODD) PT Raised to $350 at RBC Capital - StreetInsider
Insulet Corporation (NASDAQ:PODD) Q2 2025 Earnings Call Transcript - Insider Monkey
Insulet Corporation (PODD) PT Raised to $400 at Bernstein SocGen Group - StreetInsider
Insulet price target raised to $353 from $331 at Canaccord - TipRanks
Morgan Stanley Raises Price Target on Insulet to $370 From $355, Keeps Overweight Rating - MarketScreener
Goldman Sachs Adjusts Price Target on Insulet to $399 From $380, Maintains Buy Rating - MarketScreener
Canaccord Genuity Adjusts Price Target on Insulet to $353 From $331, Maintains Buy Rating - MarketScreener
Bernstein Adjusts Price Target on Insulet to $400 From $375, Maintains Outperform Rating - MarketScreener
Tandem, Insulet monitoring CMS payment proposal for diabetes tech - Yahoo Finance
Insulet raises full-year 2025 revenue growth guidance to 24%-27% as Omnipod 5 drives global adoption - MSN
Insulet Corp (PODD) Q2 2025 Earnings Call Highlights: Record Revenue and Raised Guidance Amid ... By GuruFocus - Investing.com Canada
Insulet Corporation Reports Strong Q2 2025 Growth - TipRanks
Insulet Corp. stock outperforms competitors on strong trading day - MSN
Insulet: Q2 Earnings Snapshot - Stamford Advocate
Insulet Corp. Q2 Profit Decreases, But Beats Estimates - Nasdaq
Insulet’s Earnings Call Highlights Robust Growth and Optimism - TipRanks
Canaccord Genuity raises Insulet stock price target to $353 on strong growth - Investing.com Nigeria
Insulet Corporation (PODD) PT Raised to $353 at Canaccord Genuity - StreetInsider
Insulet Ups The Pace Thanks To Demand For Its Wearable Pump - Finimize
Insulet’s Wearable Pumps Propel Earnings Past Wall Street Goals - Finimize
Leerink Partners Raises Price Target on Insulet to $339 From $333 - MarketScreener
Wells Fargo Adjusts Price Target on Insulet to $350 From $330, Maintains Overweight Rating - MarketScreener
Insulet (NASDAQ:PODD) Beats Expectations in Strong Q2, Stock Soars - Yahoo Finance
Insulet Peer Tandem Diabetes Underwhelming Earnings, Dull Outlook Drags Stock - Benzinga
Jefferies raises Insulet stock price target to $375 on strong Q2 results - Investing.com Nigeria
Insulet Lifts Annual Forecast On Increased Adoption For Insulin Pump Omnipod 5 - inkl
Jefferies Adjusts Insulet Price Target to $375 From $360, Maintains Buy Rating - MarketScreener
Insulet Corporation (PODD) PT Raised to $375 at Jefferies - StreetInsider
Insulet Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings call transcript: Insulet beats Q2 2025 forecasts, stock surges - Investing.com
Insulet Puts More Competitive Pressure on Tandem - Morningstar
Transcript : Insulet Corporation, Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Insulet's Q2 2025: Navigating Contradictions in U.S. Growth, Type 2 Diabetes Expectations, and Global Strategy - AInvest
Insulet (PODD) Q2 2025 Earnings: Sustained Growth, Margin Expansion, and Strategic Momentum - AInvest
Tandem stock down, Insulet stock up on Q2 prints (PODD:NASDAQ) - Seeking Alpha
Insulet 2025 Q2 Earnings Revenue Surges 32.9%, but Net Income Plummets 88.1% - AInvest
Insulet (PODD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
인슐렛 코퍼레이션 (PODD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.51%
1.39%
자본화:
|
볼륨(24시간):